Nautilus Biotechnology (NAUT) Stock Price, News & Analysis

Company Overview

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical imaging system for integrated fluidics and liquid handling sub-system. In addition, the company provides sample preparation, flow cells, multi-affinity probe reagents, and instrument buffers system to perform multi-cycle analysis runs. Nautilus Biotechnology, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Key Stats

• Today's Range: $0.70 to $0.73
• 50-Day Range: $0.67 to $0.82
• 52-Week Range: $0.66 to $3.09
• Volume: 236,346 shs
• Average Volume: 212,274 shs
• Market Capitalization: $89.05 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $2.13
• Consensus Rating: Sell

Nautilus Biotechnology Stock Analysis - MarketRank™

Nautilus Biotechnology scored higher than 41% of companies evaluated by MarketBeat, and ranked 672nd out of 929 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.5 / 5
• Analyst Rating: Sell

Consensus Rating

Nautilus Biotechnology has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Nautilus Biotechnology has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Nautilus Biotechnology are expected to decrease in the coming year, from ($0.57) to ($0.68) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Nautilus Biotechnology is -1.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Nautilus Biotechnology is -1.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Nautilus Biotechnology has a P/B Ratio of 0.43. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.46% of the float of Nautilus Biotechnology has been sold short.

Short Interest Ratio / Days to Cover

Nautilus Biotechnology has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Nautilus Biotechnology has recently increased by 11.15%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Nautilus Biotechnology does not currently pay a dividend.

Dividend Growth

Nautilus Biotechnology does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.46% of the float of Nautilus Biotechnology has been sold short.

Short Interest Ratio / Days to Cover

Nautilus Biotechnology has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Nautilus Biotechnology has recently increased by 11.15%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

1 people have searched for NAUT on MarketBeat in the last 30 days.

Company Ownership

• Score: 4.2 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Nautilus Biotechnology insiders have bought more of their company's stock than they have sold. Specifically, they have bought $11,550.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

41.10% of the stock of Nautilus Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

50.71% of the stock of Nautilus Biotechnology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

NAUT Stock Analysis - Frequently Asked Questions

How have NAUT shares performed this year?

Nautilus Biotechnology's stock was trading at $1.68 at the beginning of the year. Since then, NAUT shares have decreased by 58.0% and is now trading at $0.7060.

How were Nautilus Biotechnology's earnings last quarter?

Nautilus Biotechnology, Inc. (NASDAQ:NAUT) announced its quarterly earnings data on Thursday, July, 31st. The company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.14) by $0.02.
Read the conference call transcript.

Who are Nautilus Biotechnology's major shareholders?

Top institutional shareholders of Nautilus Biotechnology include Clarius Group LLC (0.84%), Geode Capital Management LLC (0.44%), Corient Private Wealth LLC (0.34%) and Jane Street Group LLC (0.23%). Insiders that own company stock include Parag Mallick, Sujal M Patel, Subramanian Sankar, Anna Mowry, Gwen E Weld and Mary E Godwin.
View institutional ownership trends.

How do I buy shares of Nautilus Biotechnology?

Shares of NAUT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Nautilus Biotechnology own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Nautilus Biotechnology investors own include JPMorgan Chase & Co. (JPM), Netflix (NFLX), Meta Platforms (META), Tesla (TSLA), NVIDIA (NVDA), Home Depot (HD) and Visa (V).

Company Calendar

• Last Earnings: 7/31/2025
• Today: 8/26/2025
• Next Earnings (Estimated): 10/28/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Measuring And Control Equipment
• Current Symbol: NASDAQ:NAUT
• CIK: 1808805
• Web: www.nautilus.bio
• Phone: 206-333-2001
• Fax: N/A
• Employees: 130
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Nautilus Biotechnology: $2.13
• High Price Target: $2.50
• Low Price Target: $1.75
• Potential Upside/Downside: +201.0%
• Consensus Rating: Sell
• Rating Score (0-4): 1.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.52)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$70.78 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -32.53%
• Return on Assets: -27.85%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 18.52
• Quick Ratio: 18.52

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.66 per share
• Price / Book: 0.43

Miscellaneous

• Outstanding Shares: 126,310,000
• Free Float: 74,394,000
• Market Cap: $89.17 million
• Optionable: Optionable
• Beta: 1.42